Karuna Therapeutics Inc. (KRTX)
NASDAQ: KRTX
· Real-Time Price · USD
329.83
0.09 (0.03%)
At close: Mar 15, 2024, 9:00 PM
Karuna Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | 654K | 5.28M | 81K | 5.28M | n/a | 36.96M | n/a | n/a | n/a |
Cost of Revenue | 447K | 458K | 469K | 327K | 305K | 290K | 269K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -447K | -458K | -469K | 327K | 4.97M | -209K | 5.01M | n/a | 36.96M | n/a | n/a | n/a |
Operating Income | -129.59M | -136.22M | -119.91M | -109.07M | -85.04M | -80.99M | -65.05M | -58.59M | -28.19M | -51.17M | -34.53M | -29.96M |
Interest Income | 16.29M | 16.95M | 16.6M | 11.35M | 9.57M | 3.88M | 490K | 237K | 139K | 114K | 106K | 143K |
Pretax Income | -113.15M | -119.12M | -103.16M | -97.57M | -75.32M | -76.96M | -64.42M | -58.22M | -27.95M | -50.93M | -34.42M | -30.5M |
Net Income | -113.82M | -119.12M | -103.16M | -86.08M | -76.21M | -69.05M | -64.94M | -57.6M | -27.96M | -50.93M | -34.42M | -30.5M |
Selling & General & Admin | 47.39M | 32.27M | 27.42M | 24.25M | 24.31M | 19.13M | 17.84M | 14.79M | 20.06M | 12.39M | 10.38M | 9.78M |
Research & Development | 82.19M | 103.95M | 92.49M | 85.47M | 66M | 61.95M | 52.49M | 43.81M | 45.09M | 38.77M | 24.15M | 20.19M |
Other Expenses | 147K | 147K | 147K | 147K | 147K | 147K | 147K | 139K | 123K | 122K | 9K | n/a |
Operating Expenses | 129.59M | 136.22M | 119.91M | 109.72M | 90.31M | 81.08M | 70.33M | 58.59M | 65.16M | 51.17M | 34.53M | 29.96M |
Interest Expense | 11.49M | n/a | n/a | n/a | 9.57M | 3.88M | 490K | 237K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 129.59M | 136.22M | 119.91M | 109.72M | 90.31M | 81.08M | 70.33M | 58.59M | 65.16M | 51.17M | 34.53M | 29.96M |
Income Tax Expense | 670K | n/a | n/a | -11.49M | 890K | -7.92M | 528K | -613K | 6K | -114K | -106K | n/a |
Shares Outstanding (Basic) | 37.78M | 37.69M | 37.52M | 34.8M | 34.41M | 32.35M | 29.9M | 29.81M | 29.69M | 29.57M | 29.48M | 27.79M |
Shares Outstanding (Diluted) | 37.78M | 37.69M | 37.52M | 34.8M | 34.41M | 32.35M | 29.9M | 29.81M | 29.69M | 29.57M | 29.48M | 27.79M |
EPS (Basic) | -3.01 | -3.16 | -2.75 | -2.47 | -2.22 | -2.13 | -2.17 | -1.93 | -0.94 | -1.72 | -1.17 | -1.1 |
EPS (Diluted) | -3.01 | -3.16 | -2.75 | -2.47 | -2.22 | -2.13 | -2.17 | -1.93 | -0.94 | -1.72 | -1.17 | -1.1 |
EBITDA | -129.14M | -136.22M | -119.91M | -109.07M | -85.04M | -80.7M | -64.78M | -58.35M | -28.17M | -51.06M | -34.48M | -29.17M |
EBIT | -101.66M | -136.22M | -119.91M | -109.07M | -65.75M | -73.08M | -63.92M | -57.98M | -28.19M | -51.17M | -34.53M | n/a |
Depreciation & Amortization | 447K | 458K | 469K | 327K | 305K | 290K | 269K | 248K | 236K | 106K | 52K | 112K |